Evidence map›Paper›PMID 42591790›Full record

ArticleFrontiers in immunology2026

A novel region of the insulin B9-23 sequence is targeted by a HIP-reactive diabetogenic T cell clone.

Janet M Wenzlau, Kaitlin Mangold, Kelli Nicholson, Mylinh Dang, Anita C Hohenstein, Kelly S Douglas, James E DiLisio, Roger Powell, Thomas Delong, Kathryn Haskins and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Janet M WenzlauDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Kaitlin MangoldDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Kelli NicholsonDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Mylinh DangDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States.
Anita C HohensteinDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Kelly S DouglasDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States.
James E DiLisioDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Roger PowellDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States.
Thomas DelongDepartment of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States.
Kathryn HaskinsDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Rocky L BakerDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Hybrid Peptides as Autoantigens for Diabetogenic CD4 T CellsR01DK081166 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HASKINS, KATHRYN M, JAMES, EDDIE A · 2011 to 2024
$7.3M
Characterize the Landscape and Origin of Hybrid Peptides in Beta CellsR01DK119529 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI THOMAS DELONG · 2018 to 2026
$4.8M
Responses to Hybrid Insulin Peptides as Biomarkers of Disease Activity in Human Type 1 DiabetesR01AI146202 · NIAID · UNIVERSITY OF COLORADO DENVER · PI BAKER, ROCKY LEE · 2020 to 2024
$1.9M
NCI NIH HHS P30 CA046934NIAID NIH HHS R01 AI146202NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK081166NIDDK NIH HHS R01 DK119529
6 · The paper itself

Abstract

Type 1 Diabetes (T1D) is an organ-specific autoimmune disease in which T cells are major drivers, leading to the destruction of beta-cells and insulin deficiency. Although the B-chain of insulin is a critical target for islet-reactive CD4 T cells, the native sequence is poorly antigenic and

Indexed as

CD4-Positive T-LymphocytesDiabetes Mellitus, Type 1InsulinPeptide FragmentsAmino Acid SequenceAnimalsCathepsin DFemaleHumansMiceMice, Inbred NODProinsulinProtein Processing, Post-TranslationalCathepsin DInsulininsulin B (9-23)Peptide FragmentsProinsulinautoimmunityCD4 T cellshybrid insulin peptides (HIPs)insulin B-chainNOD mouse modeltype 1 diabetes

Identifiers

PMID42591790
PMCPMC13462851

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.